What are the neuroendocrine cells in prostate cancer? From where are these cells derived? What is the clinical implication of neuroendocrine differentiation in prostate cancer?


Neuroendocrine cells are the third type of prostatic epithelial cells in addition to secretory cells and basal cells in normal prostate glands. Neuroendocrine cells in prostate cancer are believed to derive from neuroendocrine cells or their stem precursors.


Prostate Cancer Androgen Receptor Hepatocyte Growth Factor Radical Prostatectomy Neuroendocrine Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange P, Vessella RL (2003) Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 34:646–653.PubMedCrossRefGoogle Scholar
  2. 2.
    Di Sant’Agnese PA, de Mesy Jensen KL (1984) Endocrine-paracrine cells of the prostate: an ultrastructural study. Hum Pathol 15:1034–1044.PubMedCrossRefGoogle Scholar
  3. 3.
    Taupenot L, Harper KL, OConner DT (2003) Mechanisms of disease: the chromogranin-secretogranin family. N Engl J Med 348:1134–1149.PubMedCrossRefGoogle Scholar
  4. 4.
    Kadmon D, Thompson TC, Lynch GR, Scardino PT (1991) Elevated plasma chromogranin-A concentration in prostatic carcinoma. J Urol 146:358–361.PubMedGoogle Scholar
  5. 5.
    Abrahamsson, P-A (1999) Neuroendocrine differentiation in prostatic carcinoma. Prostate 39:135–148.PubMedCrossRefGoogle Scholar
  6. 6.
    Di Sant’Agnese PA, de Mesy Jensen KL, Chrukian CJ, Agarwal MK (1985) Human prostatic endocrineparacrine (APUD) cells. Arch Pathol Lab Med 109: 607–612.PubMedGoogle Scholar
  7. 7.
    Di Sant’Agnese PA (1995) Neuroendocrine differentiation in prostatic carcinoma. Cancer (suppl) 75:1850–1859.CrossRefGoogle Scholar
  8. 8.
    Noordzij MA, van der Kwast TH, van Steenbrugge GJ, Hop WJC, Schroeder FH (1995) The prognostic influence of neuroendocrine cells in prostate cancer: results of a long-term follow-up study with patients treated with radical prostatectomy. Int J Cancer 62:252–258.PubMedCrossRefGoogle Scholar
  9. 9.
    Di Sant’Agnese PA (1992) Neuroendocrine differentiation in carcinoma of the prostate. Cancer 70:254–268.PubMedCrossRefGoogle Scholar
  10. 10.
    Bonkhoff H, Remberger K (1996) Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 28:98–106.PubMedCrossRefGoogle Scholar
  11. 11.
    Xue Y, Verhofstad A, Lange W, Smedts F, Debruyne F, de la Rossette J, Schalkan J (1997) Prostate neuroendocrine cells have a unique keratin expression pattern and do not express Bcl-2. Am J Pathol 151:1759–1765.PubMedGoogle Scholar
  12. 12.
    Isaacs JT, Coffey DS (1989) Etiology and disease process of benign prostatic hyperplasia. Prostate 2(suppl):33–50.CrossRefGoogle Scholar
  13. 13.
    Verhagen APM, Raemaker FCS, Aalders TW, Shaafsma HE, Debruyne MJ, Schalken JA (1992) Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res 52:6182–6187.PubMedGoogle Scholar
  14. 14.
    Xue Y, Smedt F, Debruyne FMJ, de la Rosette JJMDH, Shalkan J (1998) Identification of intermediate cell types by keratin expression in the developing human prostate. Prostate 34:292–301.PubMedCrossRefGoogle Scholar
  15. 15.
    Bonkhoff H, Stein U, Remberger K (1994) The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate 24:114–118.PubMedCrossRefGoogle Scholar
  16. 16.
    Nakada SY, di Sant’Agnese PA, Moynes RA, Hiipakka RA, Liao S, Cockett TK, Abrahamsson P-A (1993) The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue. Cancer Res 53:1967–1970.PubMedGoogle Scholar
  17. 17.
    Bonkhoff H, Stein U, Remberger K (1993) Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate. Virchows Arch A Pathol Anat 423:291–294.CrossRefGoogle Scholar
  18. 18.
    Bonkhoff H, Stein U, Remberger K (1994) Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. Hum Pathol 25:42–46.PubMedCrossRefGoogle Scholar
  19. 19.
    Bonkhoff H, Remberger K (1993) Widespread distribution of nuclear androgen receptors in the basal layer of the normal and hyperplastic human prostate. Virchows Arch A Pathol Anat 422:35–38.CrossRefGoogle Scholar
  20. 20.
    Bonkhoff H, Wernert N, Dhom G, Remberger K (1991) Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate 19:91–98.PubMedCrossRefGoogle Scholar
  21. 21.
    Ahlgren G, Pedersen K, Aus G, Hugosson J, Abahamsson P-A (2000) Progressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment. Prostate 42:274–279.PubMedCrossRefGoogle Scholar
  22. 22.
    Aprikian AG, Cordon-Cardo C, Fair WR, Zhang Z-F, Bezinet M, Hamdy SF, Reuter VE (1994) Neuroendocrine differentiation in metastatic prostatic carcinoma. J Urol 151:914–919.PubMedGoogle Scholar
  23. 23.
    Jibron T, Bjartell A, Abrahamsson P-A (1998) Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology 51:585–589.CrossRefGoogle Scholar
  24. 24.
    Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJM, van der Kwast TH, Schroeder FH, van Steenbrugge GJ (1999) Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model. Am J Pathol 154:543–551.PubMedGoogle Scholar
  25. 25.
    Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJM, van der Kwast TH, Schroeder FH, van Steenbrugge GJ (2000) Androgen deprivation of the pro-hormone convertase-310 human prostate cancer model system induces neuroendocrine differentiation. Cancer Res 60:741–748.PubMedGoogle Scholar
  26. 26.
    Cohen RJ, Glezerson G, Haffejee Z (1991) Neuroendocrine cells: a new prognostic parameter in prostate cancer. Br J Urol 68:258–262.PubMedCrossRefGoogle Scholar
  27. 27.
    Glezerson G, Cohen RJ (1991) Prognostic value of neuroendocrine cells in prostatic adenocarcinoma. J Urol 145(suppl):296A.Google Scholar
  28. 28.
    McWilliams LJ, Manson C, George NJR (1997) Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma. Br J Urol 80:287–290.Google Scholar
  29. 29.
    Krijnen JL, Bogdanowicz JAFT, Seldenrijk CA, Mulder PGH, van der Kwast TH (1997) The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol 158:171–174.PubMedCrossRefGoogle Scholar
  30. 30.
    Paul R, Chang P, di Sant’Agnese PA, Cockett TK, Abrahamsson P-A (1993) Prognostic significance of neuroendocrine differentiation in biopsy specimens from patients with metastatic prostate cancer. J Urol 149(suppl):480A.Google Scholar
  31. 31.
    Cohen MK, Arber DA, Coffield S, Keegan GT, McCLintock J, Speights Jr VO (1994) Neuroendocrine differentiation in prostate adenocarcinoma and its relationship to tumor progression. Cancer 74:1899–1903.PubMedCrossRefGoogle Scholar
  32. 32.
    Bubendorf L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P, Miihatch MJ (1996) Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 178:437–441.PubMedCrossRefGoogle Scholar
  33. 33.
    Nakashiro K, Okamoto M, Hayashi Y, Oyasu R (2000) Hepatocyte growth factor secreted by prostate-derived stromal cells stimulates growth of androgen-independent human prostatic carcinoma cells. Am J Pathol 157:795–803.PubMedGoogle Scholar
  34. 34.
    Nakashiro K, Hara S, Shinohara Y, Oyasu M, Kawamata H, Shintani S, Hamakawa H, Oyasu R (2004) Phenotypic switch from paracrine to autocrine role of hepatocyte growth factor in an androgen-independent human prostatic carcinoma cell line, CWR22R. Am J Pathol 165:533–540.PubMedGoogle Scholar
  35. 35.
    Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT, Day ML (1995) Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 147:386–396.PubMedGoogle Scholar

Copyright information

© Springer 2008

Personalised recommendations